Sleep Medicine India: Drug Classes & Regulation
A clinical overview of sleep medicine india: insomnia drug classes, OSA management, CDSCO scheduling of hypnotics, and hospital pharmacy stocking.
This piece covers the drug classes used in sleep medicine india, how CDSCO regulates them, what OSA management looks like when it isn't pharmacological, and why hospital pharmacy stocking of Schedule H1 hypnotics matters operationally.
How common is insomnia in India, and who treats it?
Insomnia is treated first by general physicians and psychiatrists. Referral to a sleep specialist or pulmonologist follows only when OSA is suspected. Systematic review data across Indian population studies put pooled insomnia prevalence at approximately 25.7%, with several individual studies reporting figures above 30% in older adults.
The Indian Psychiatric Society's clinical practice guidelines for sleep disorders, published in the Indian Journal of Psychiatry, frame insomnia management around treating underlying causes first: depression, anxiety, pain, thyroid disease. Pharmacological options come after that. Chronic primary insomnia gets a shorter list of appropriate drug classes than the informal "sleeping pill" market suggests.
What drug classes are used for insomnia in sleep medicine india?
Three drug classes dominate insomnia prescribing in sleep medicine india: non-benzodiazepine "Z-drugs" (zolpidem, zopiclone), short-acting benzodiazepines, and melatonin receptor agonists for circadian-rhythm complaints. Each has a different regulatory tier and a different evidence base for how long it should be used.
Z-drugs act on the same GABA-A receptor that benzodiazepines target, but with more selective binding. That selectivity is the pharmacological basis for their shorter half-life and comparatively lower next-day sedation. An observational pre-post study of sedative-hypnotic use among Indian insomnia patients, published via PMC, found measurable improvement in subjective sleep quality over a short treatment course. The evidence base frames these agents as short-term tools, not maintenance therapy.
Trazodone and low-dose sedating antidepressants are also used off-label, particularly where anxiety or depression coexists with insomnia. This reflects a treat-the-cause approach rather than a hypnotic-first one, and it is the pattern the Indian Psychiatric Society guidelines explicitly favour.
How does CDSCO regulate sleep medications in India?
Zolpidem and related Z-drugs sit in Schedule H1 of the Drugs and Cosmetics Rules 1945. Every dispensation requires the prescription to be retained by the pharmacy, recorded in a register, and made available for regulatory inspection — a materially tighter control than an ordinary Schedule H drug.
India's Drugs Technical Advisory Board (DTAB) considered and rejected an industry proposal to move zolpidem out of Schedule H1 into the less-restricted Schedule H. The board's own meeting minutes record the reasoning: the drug carries genuine dependence potential. Schedule H1 itself was created by a 2013 gazette notification to bring habit-forming drugs, certain antibiotics and anti-TB drugs under stricter retail control.
For a pharmacy, this means Schedule H1 hypnotics need a separate register. They cannot be dispensed on a photocopied or repeat prescription without a fresh original, and they carry real inspection risk if that paperwork lapses.
Is obstructive sleep apnea treated with drugs?
No first-line drug exists for OSA within sleep medicine india. The Indian initiative on obstructive sleep apnea (INOSA) guidelines were developed under the Ministry of Health and Family Welfare's Department of Health Research, with ICMR support and AIIMS New Delhi convenership. They set continuous positive airway pressure (CPAP) as primary treatment for moderate-to-severe OSA, with weight management, positional therapy and, in selected cases, surgical airway correction as adjuncts.
The guidelines exist because awareness of OSA among Indian primary-care physicians was found to be poor. They also exist because Western OSA protocols do not map cleanly onto Indian body-habitus and comorbidity patterns. CPAP devices and consumables, not pharmacy drug stock, are the relevant supply chain for this condition, which sets it apart from every other drug class in this overview.
What should a hospital pharmacy stock for sleep medicine india?
A hospital pharmacy serving both a psychiatry/sleep-medicine outpatient department and a general ward needs different registers and different supply chains for the same broad "sleep medicine" label. The table below breaks out what actually needs to be stocked, and under what compliance regime.
| Category | Examples | Regulatory status | Stocking consideration |
|---|---|---|---|
| Z-drugs | Zolpidem, zopiclone | Schedule H1 | Separate register, original Rx only, inspection risk |
| Benzodiazepines (short-acting) | Prescriber-specific, short courses | Schedule H / H1 by formulation | Same register discipline as above |
| Melatonin / MRAs | Circadian-rhythm complaints | Schedule H in most formulations | Lower control burden, still Rx-only |
| Sedating antidepressants (off-label) | Used where mood disorder coexists | Schedule H | Standard prescription stock |
| CPAP consumables | Masks, tubing, filters | Medical device, not scheduled drug | Biomedical/device stock, separate from H1 register |
Why does hypnotic stocking discipline matter to a hospital pharmacy?
A hospital that prescribes a Schedule H1 hypnotic but cannot dispense it in-house, whether the register has lapsed or the drug simply is not stocked, sends that prescription to an outside chemist. It loses the visibility a hospital needs into whether a patient is refilling a habit-forming medicine more often than the treating doctor intended. That is a safety gap, not just a lost sale.
Our managed hospital pharmacy services guide covers how a properly run in-house pharmacy keeps Schedule H1 register compliance current instead of ad hoc. Our prescription leakage guide covers what it costs a hospital when prescriptions routinely walk out to a nearby chemist instead of being filled on-site. Our hospital pharmacy management guide covers the broader register and inventory discipline a Schedule H1-heavy formulary demands.
Sources
- 1Systematic Review of Prevalence of Sleep Problems in India: A Wake-up Call for Promotion of Sleep Health — medRxiv preprint, 2023
- 2Clinical Practice Guidelines for Sleep Disorders — Indian Journal of Psychiatry, Indian Psychiatric Society, Gupta et al., 2017
- 3Effects of sedative-hypnotics on sleep quality among patients with insomnia: evidence from an observational, pre-post study in India — National Institutes of Health, National Library of Medicine
- 4Minutes of the 90th DTAB meeting — Central Drugs Standard Control Organisation
- 5Consensus and evidence-based Indian initiative on obstructive sleep apnea guidelines 2014 (first edition) — Lung India, Department of Health Research, MoHFW / ICMR / AIIMS New Delhi
This article is for informational purposes and is not a substitute for professional medical advice. It describes drug classes and regulatory status for clinical reference; it is not a prescribing guide and does not recommend any treatment for a specific patient. Consult a qualified sleep medicine specialist or physician for diagnosis and treatment.
FAQ
Frequently asked questions
No. Z-drugs and most benzodiazepine hypnotics fall under Schedule H1 of the Drugs and Cosmetics Rules 1945, requiring a retained original prescription and pharmacy register entry. They cannot legally be sold over the counter or on a repeat prescription without a fresh original.
Insomnia is managed with short-term sedative-hypnotic drugs and cause-directed treatment of underlying conditions. OSA has no first-line drug therapy; the INOSA guidelines set CPAP, weight management and positional therapy as primary treatment.
India's DTAB reviewed and rejected an industry request to relax zolpidem's schedule, concluding the drug carries genuine dependence potential that justifies the stricter H1 controls, including mandatory register-keeping by the dispensing pharmacy.
Pooled estimates from Indian population studies put insomnia prevalence at roughly 25.7% of adults, with meaningfully higher rates reported among older adults and those with diabetes or cardiovascular disease.
Melatonin-based products generally carry a lower control burden than Z-drugs or benzodiazepines, but formulations sold as prescription drugs still require a valid prescription; over-the-counter availability varies by formulation and manufacturer registration.
It depends on the diagnosis. Insomnia care in sleep medicine india leans on short-term drug therapy; OSA care leans almost entirely on CPAP devices and behavioural change, with drugs playing essentially no first-line role.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.